Key result
The combined treatment of ACE inhibitors, statins, muscarinic antibody immunoadsorbents, and fungicidal drugs may offer therapeutic possibilities to prevent cardiomyopathy progression in Chagas disease.
A proposed risk score and combined pharmacological strategy aim to prevent the progression of cardiomyopathy in patients with chronic Chagas disease.
Hypothesis-generating for combined therapy in Chagas cardiomyopathy; prospective RCTs needed before any clinical adoption.
There is some published evidence suggesting micro vascular endothelial dysfunction and dysautonomia involvement in Chagas disease in association with cardiomyocyte changes favoring disease progression. The combined treatment between angiotensin converting enzyme (ACE) inhibitor drugs; Simvastatin, muscarinic antibody immunoadsorbent together with fungicidal drugs would open therapeutic possibilities in this disease.
No takes yet. Share an insight, caveat, or question.
Mitelman et al. (2013) conducted a review in Chagas Disease. ACE inhibitors, statins, and muscarinic antibody immunoadsorbent was evaluated. The combined treatment of ACE inhibitors, statins, muscarinic antibody immunoadsorbents, and fungicidal drugs may offer therapeutic possibilities to prevent cardiomyopathy progression in Chagas disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: